Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Newsfile - Tue Sep 17, 7:14AM CDT

Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA Newsfile - Mon Sep 16, 7:14AM CDT

Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference Newsfile - Mon Sep 9, 6:08AM CDT

Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series Newsfile - Thu Aug 29, 7:42AM CDT

Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Newsfile - Wed Aug 14, 4:14PM CDT

Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound Newsfile - Tue Aug 6, 7:08AM CDT

Phio's INTASYL compound targets aging skin disordersMarlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Announces New Chief Financial Officer Newsfile - Thu Aug 1, 7:06AM CDT

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds Newsfile - Fri Jul 12, 7:04AM CDT

Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 Newsfile - Mon Jul 8, 7:02AM CDT

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

PHIO : 3.66 (-0.96%)
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds Newsfile - Fri Jul 5, 7:02AM CDT

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology...

PHIO : 3.66 (-0.96%)

Barchart Exclusives

Down 13% YTD, Should You Buy the Dip in This Warren Buffett Energy Stock? Barchart - 10 minutes ago
Occidental Petroleum is an oil and gas stock that is also part of Warren Buffett's equity portfolio. Trading at a cheap valuation, is OXY a good stock to own right now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot